Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) director & chief medical advisor Dr Alan Dunton and executive chairman Dr John Prendergast talked with Proactive’s Tylah Tully about the company’s latest Phase 2 clinical trial results for RECCE® 327, a topical gel targeting Diabetic Foot Infections (DFIs) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Dr Dunton explained that the Phase 2 study was conducted across three sites in Australia, testing the gel in 30 patients. The results showed a 93% cure or improvement rate after two weeks of treatment, with 82% of patients responding positively within the first week. He highlighted the gel’s strong efficacy, noting that unlike many antibiotics, R327G did not develop bacterial resistance. Dr Prendergast emphasised that these findings provided confidence as Recce moved toward regulatory approval. He revealed that the upcoming registration Phase 3 trial in Indonesia, originally planned for 300 patients, may achieve meaningful interim data in as few as 100 patients. This could fast-track approval within a shorter timeframe, potentially 12 months. Both executives underscored the clinical potential of R327G, particularly in tackling antibiotic-resistant infections. With its first-in-class synthetic antibiotic properties, the gel could become a game-changer in infection treatment. #ReccePharmaceuticals #ASXRCE #Biotech #ClinicalTrials #Recce327 #Antibiotics #DiabeticFootUlcer #ABSSSI #DrugDevelopment #MedicalResearch #StockMarket